Consulta las presentaciones y los estudios destacados en ESMO 2026.
Presentaciones orales
25.10.2026, 16:30 - 18:15
Primary analysis of Krascendo 1: A head-to-head, randomised, phase III trial of divarasib vs sotorasib (soto) and adagrasib (ada) in previously treated locally advanced or metastatic KRAS G12C+ NSCLC
Molécula / tratamiento
Divarasib
Autoría
Ferdinandos Skoulidis
Sesión / ubicación
Presidential Symposium II Alicante Auditorium - Hall 6
25.10.2026, 08.30 - 10.00
Immunogenomic signature associated with ICI-related pneumonitis in non-small-cell lung cancer (NSCLC) patients
Molécula / tratamiento
NA
Autoría
Jarushka Naidoo
Sesión / ubicación
Rapid oral 1: Basic science and translational research, Leon Auditorium - Hall 4
Pósteres Roche
23.10.2026, 15:15 - 16:00
Tambotatug pelitecan (YL201): Analyses of interstitial lung disease in patients with advanced solid tumours from Phase 1/2 studies
Molécula / tratamiento
Tambotatug pelitecan
Autoría
Siqing Fu
Sesión / ubicación
Poster session: Developmental therapeutics (1057P) Poster Area Hall 5
23.10.2026, 15:15 - 16:00
Phase 1 First-in-Human (FIH) Results of YL211, a c-Met targeting Antibody-Drug Conjugate (ADC), in patients (pts) with Advanced Solid Tumors
Molécula / tratamiento
YL211
Autoría
Shiraj Sen
Sesión / ubicación
Poster session: Developmental therapeutics (1017P) Poster Area Hall 5
26.10.2026, 12:00 - 12.45
Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II–IIIB, KRAS G12C+ non-small cell lung cancer
Molécula / tratamiento
Divarasib
Autoría
Solange Peters
Sesión / ubicación
Poster session: NSCLC, early stage (2551TiP) Poster Area Hall 5
26.10.2026, 12:00 - 12.45
Tambotatug pelitecan (YL201): Efficacy and safety in locally advanced/metastatic NSCLC from a phase 1 study
Molécula / tratamiento
Tambotatug pelitecan
Autoría
Stephen V. Liu
Sesión / ubicación
Poster session: NSCLC, locally advanced (2577P) Poster Area Hall 5
Estudios independientes financiados por Roche (IIS)
24.10.2026, 13:30–14:00
Workforce Sustainability and Oncology Nursing Capacity: Healthcare Professionals’ Perceptions of Atezolizumab SC vs IV in the Spanish IMscin002 Cohort
Molécula / tratamiento
Atezolizumab
Autoría
Jorgina Serra López
Sesión / ubicación
Poster session: Cancer Nursing. Workforce developement of the future(CN94) Poster Area Hall 5
